Unione Europea - italiano - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - infezioni da hiv - antivirali per uso sistemico - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viiv healthcare gmbh - dolutegravirum, abacavirum, lamivudinum - compresse rivestite con film - dolutegravirum 50 mg a dolutegravirum natricum, abacavirum 600 mg per abacaviri sulfas, lamivudinum 300 mg, mannitolum, cellulosum microcristallinum, povidonum k 29-32, carboxymethylamylum natricum, magnesio stearas, Überzug: talco, macrogolum, poli(alcole vinylicus), e 171, e 172, per compresso haze corrisp. sodio 6.5 - 8.93 mg. - l'infezione da hiv - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viiv healthcare gmbh - dolutegravirum, abacavirum, lamivudinum - compresse per sospensione orale - dolutegravirum 5 mg ut dolutegravirum natricum, abacavirum 60 mg ut abacaviri sulfas, lamivudinum 30 mg, mannitolum, cellulosum microcristallinum, povidonum k 29-32, carboxymethylamylum natricum a, cellulosum microcristallinum silicificatum, crospovidonum, acesulfamum kalicum, sucralosum, natrii stearylis fumaras, aromatica erdbeercrèmearoma, Überzug: talcum, macrogolum 4000, poly(alcohol vinylicus), e 171, e 172 (flavum), pro compresso obducto corresp. natrium 0.9 mg. - l'infezione da hiv - synthetika